PANCREATITIS-ASSOCIATED PROTEIN, A NOVEL BIOMARKER FOR HEART FAILURE, IS INCREASED IN PATIENTS WITH SEVERE CHRONIC CHAGAS CARDIOMYOPATHY

LONGHI SILVIA A; NATALIA JUIZ; IOVANNA JUAN L; GISELA MORALES SANFURGO; SCHIJMAN ALEJANDRO G; PAULA BEATI

Buenos Aires

Congreso; REUNIÓN CONJUNTA DE SOCIEDADES DE BIOCIENCIAS-XXIX REUNIÓN ANUAL DE LA SOCIEDAD ARGENTINA DE PROTOZOOLOGÍA; 2017

Sociedad Argentina de Protozoologia

Chronic Chagas Cardiomyopathy (CCC) manifests as a dilated cardiomyopathy and includes arrhythmias, atrioventricular and intraventricular conduction disorders, apical aneurysms, cardiomegaly and heart failure. In Chagas disease, it is important to identify patients who still asymptomatic, have risk of progressing to CCC. We aimed to determine the circulating levels of different biomarkers in serum of patients with CCC and to evaluate if their concentrations correlate and/or predict the severity of the disease. The study was carried in 72 chronic patients and 15 non-infected donors. Patients were classified according to the Consensus on Chagas-Mazza Disease in non-demonstrated (non-DC, n=23) or demonstrated (DC) pathology groups; the latter group was subclassified in patients with arrhythmias (DC-Arr, n=25) or with congestive heart failure (DC-CHF, n=24). Interleukin (IL) 6, IL10, Tumor Necrosis Factor α (TNFα) and Pancreatitis-Associated Protein 1 (PAP1) were measured using ELISA kits. Our results showed higher levels of IL6 in sera of DC patients compared to non-DC patients (p=0.035). PAP1 level was significantly higher in DC-CHF vs DC-Arr or non-DC (p